Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A

Understanding how best to treat aspects of Fragile X syndrome has the potential to improve the quality of life of affected individuals. Such an effective therapy has, as yet, remained elusive. In this article, we ask those researching or affected by Fragile X syndrome their views on the current stat...

Descripción completa

Detalles Bibliográficos
Autores principales: Alusi, Ghassan, Berry-Kravis, Elizabeth, Nelson, David, Orefice, Lauren L., Booker, Sam A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782331/
https://www.ncbi.nlm.nih.gov/pubmed/36475635
http://dx.doi.org/10.1021/acschemneuro.2c00674
_version_ 1784857317053825024
author Alusi, Ghassan
Berry-Kravis, Elizabeth
Nelson, David
Orefice, Lauren L.
Booker, Sam A.
author_facet Alusi, Ghassan
Berry-Kravis, Elizabeth
Nelson, David
Orefice, Lauren L.
Booker, Sam A.
author_sort Alusi, Ghassan
collection PubMed
description Understanding how best to treat aspects of Fragile X syndrome has the potential to improve the quality of life of affected individuals. Such an effective therapy has, as yet, remained elusive. In this article, we ask those researching or affected by Fragile X syndrome their views on the current state of research and from where they feel the most likely therapy may emerge.
format Online
Article
Text
id pubmed-9782331
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-97823312022-12-24 Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A Alusi, Ghassan Berry-Kravis, Elizabeth Nelson, David Orefice, Lauren L. Booker, Sam A. ACS Chem Neurosci Understanding how best to treat aspects of Fragile X syndrome has the potential to improve the quality of life of affected individuals. Such an effective therapy has, as yet, remained elusive. In this article, we ask those researching or affected by Fragile X syndrome their views on the current state of research and from where they feel the most likely therapy may emerge. American Chemical Society 2022-12-07 /pmc/articles/PMC9782331/ /pubmed/36475635 http://dx.doi.org/10.1021/acschemneuro.2c00674 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Alusi, Ghassan
Berry-Kravis, Elizabeth
Nelson, David
Orefice, Lauren L.
Booker, Sam A.
Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A
title Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A
title_full Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A
title_fullStr Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A
title_full_unstemmed Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A
title_short Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A
title_sort emerging therapeutic strategies for fragile x syndrome: q&a
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782331/
https://www.ncbi.nlm.nih.gov/pubmed/36475635
http://dx.doi.org/10.1021/acschemneuro.2c00674
work_keys_str_mv AT alusighassan emergingtherapeuticstrategiesforfragilexsyndromeqa
AT berrykraviselizabeth emergingtherapeuticstrategiesforfragilexsyndromeqa
AT nelsondavid emergingtherapeuticstrategiesforfragilexsyndromeqa
AT oreficelaurenl emergingtherapeuticstrategiesforfragilexsyndromeqa
AT bookersama emergingtherapeuticstrategiesforfragilexsyndromeqa

Ejemplares similares